Aimedis: Smart contract medical data access and more

bonanza-kreep (66)in #blockchain • 6 years ago

Data can be a matter of life and death. Nowhere is this more true than in the field of medicine. But while eHealth technology, which focuses on making medical data easily accessible online, has come far over the last two decades, many obstacles to its widespread adaptation remain. Security, privacy and trust concerns have kept patients and medical professionals from making wider use of those developments. eHealth is also held back from its full potential by limited interoperability between different systems and various other design flaws.

https://aim.aimedis.com/

Aimedis plans to do nothing less than reinvent the medical data infrastructure. By moving it to a blockchain platform, it hopes to provide patients with both privacy and control over the way their data is shared while ensuring the transparency and immutability of a broad swathe of data in the healthcare ecosystem. Later it hopes to use AI algorithms integrated with the platform to revolutionise medical research and healthcare practices.

How will Aimedis serve its users?

Aimedis plans to cater to all sides of the healthcare ecosystem, from patients, doctors and hospitals to pharmaceutical and insurance companies. All of them will be able to register on the platform through PCs, mobile apps or hospital systems, though medical professionals and organisations will need to verify their professional status and hold AIM tokens valued at 20,000 USD to use the platform. On registering, patients and their healthcare providers will start to upload information to the platform. This information will include both their electronic health records and related files such as treatment logs and raw data from IoT devices or web browsing habits, all of which will be encrypted and uploaded to the AIMChain. This private chain will be used for data storage and transfers and will be linked to a public chain used for AIM token transactions.

Smart contracts will be used for many different functions on the Aimedis platform. The main one would have to do with giving access to relevant parts of patient data to the appropriate participants, such as doctors or caregivers. The patients' current physicians could receive alerts from remote monitoring devices integrated into the system. Users will also have the option of selling some part of their anonymised data to pharmaceutical companies and other researchers in exchange for an AIM reward. They will be able to set their own information preferences and respond to specific prompts from interested buyers. Smart contracts will also be used to ensure that only currently certified professionals will have access to patient records. Finally, patients could use smart contracts to register their preferences for invasive surgery and end-of-life practices or to delegate their decisions to someone else through the multi-signature system.

The platform's AIMedisafe online pharmacy will provide pharmaceuticals with delivery tracked through chips, while its video library will contain assorted instructional and educational healthcare-related materials for a broad base of users. The AIMSocial medical social network will allow users to share content and upvote it or make direct contributions with AIM tokens. 20% of all platform revenue will go to the AIMSocial fund used for the platform's own token reward scheme. AIM tokens could also be used to pay with a discount throughout the platform. Last but not least, Aimedis' use of AI will be based on AIMedibots used to crawl the anonymous section of its database and collect and cross-reference data. This would help generate insights, run trials and discover unexpected drug side-effects and interactions. In due time, Aimedis will begin to use AI for diagnoses and therapy as well. One possible use would be to make qualified recommendations for different pharmaceuticals.

What makes Aimedis stand out?

By putting together a unified database of immutable medical information, Aimedis could do a great service to the entire health sector. It would greatly increase the utility of electronic health records and other such eHealth technologies. Telemedicine in particular could benefit from its dedicated smart contracts. Hospitals could reap economic benefits from simplified medical tourism. Insurance companies would find it much easier to process claims. Medical research would win a lot from this as well. Everyone has a vested interest in the development of medicine, and combined with the token incentive scheme, this should result to a large amount of data being made available without the ethical problems that tend to accompany the current data gathering model.

The Aimedis team includes many experienced medical professionals. It has already developed a medical platform aimed at German-speaking countries in 2012, along with other eHealth projects. Aimedis 1.0 was launched in a closed environment in 2017 and is being used by several German hospitals. As such, the company can point to a ready and tested product as well as to its active partners and experience in the field. To ensure interoperability, Aimedis will provide SDKs. It will also develop special modules to fit the specific needs of partner organisations. The main business operations will be based out of the Netherlands and Switzerland, and will meet those countries' high regulatory standards with the help of a Swiss law firm. At the same time, the company has already started to expand around the world, with a special focus on Asian countries.

https://aim.aimedis.com/

Token sale details

The token presale has already started, but the public sale date has not yet been announced, despite earlier plans to begin in June. It is now expected to come at some point in Q3 2018.

The future of electronic healthcare

Aimedis has an undeniably ambitious plan for transforming the healthcare ecosystem. Its terms (both for the token sale and for participation in the platform) can be seen as somewhat pricey. It has also already encountered some setbacks and delays. On the other hand, it has an undeniably qualified team (at least when it comes to medtech); a tested MVP; and a product that could not help but attract attention and support, given how useful it could be.

On the whole, even with enough support, Aimedis will probably take some time to come into its own. But with the collaboration of enough healthcare partners and the development of its AI engine and database, its value to its users and investors should grow exponentially over time. It just might bring about a much-delayed eHealth breakthrough and become a key player in an upgraded healthcare ecosystem.